← All indications
Lymphoma, Large-Cell, Anaplastic
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called hallmark cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
Drugs by status
Approved for this indication (1)
Phase 4 trials (16)
Phase 3 trials (8)
Phase 2 trials (64)
- methylprednisolone
- 7-hydroxystaurosporine
- ibritumomab tiuxetan
- sorafenib
- venetoclax
- bendamustine
- binimetinib
- brigatinib
- busulfan
- lenalidomide
- ceritinib
- clofarabine
- nelarabine
- denileukin diftitox
- entrectinib
- tacrolimus
- imatinib
- lapatinib
- Filgrastim
- nivolumab
- ixabepilone
- pembrolizumab
- lorlatinib
- alisertib
- msk-2206
- onalespib
- panobinostat
- carmustine
- zarnestra
- ipilimumab
- +34 more
Phase 1 trials (53)
- di-leu16-il2
- fau
- azacitidine
- dexrazoxane
- afm13
- alvespimycin
- avelumab
- irinotecan
- carfilzomib
- cilengitide
- devimistat
- duvelisib
- entinostat
- genetically engineered lymphocyte therapy
- ar-42
- rifampin
- Luminespib
- in111 anti-cd45 monoclonal antibody bc8
- methoxyamine
- morab-004
- sunitinib
- interleukin-15
- ro4929097
- sapanisertib
- dasatinib
- tetanus-cmv fusion peptide vaccine
- topotecan
- triapine
- itraconazole
- capecitabine
- +23 more
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (58)
- Spectrum Pharmaceuticals
- Takeda
- Celgene
- Bristol-Myers Squibb
- Merck
- Genzyme
- Pfizer
- Novartis
- Ariad Pharmaceuticals
- BeOne Medicines
- Ignyta, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Arizona
- AIDS Malignancy Consortium
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cancer Research UK
- Children's Cancer Group, China
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- Katholieke Universiteit Leuven
- Korea Cancer Center Hospital
- +28 more
Organization Involved with Phase 1 Indications (23)
- Amgen
- Morphotek
- Arno Therapeutics
- Celator Pharmaceuticals
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Tessa Therapeutics
- Huazhong University of Science and Technology
- University of Pittsburgh
- Johns Hopkins University
- Wake Forest University
- Wayne State University
- University of Cincinnati
- University of Colorado, Denver
- Xencor
- Weifang People's Hospital
- University of North Carolina at Chapel Hill
- University of Wisconsin
- University of Alabama, Birmingham
- Washington University in St. Louis
- Immune Cell Therapy Inc.
- Damon Runyon Cancer Research Foundation
- Wuhan Bio-Raid Biotechnology Co, Ltd. China
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (4)